Certara/$CERT
1D1W1MYTD1Y5YMAX
Capital at risk
About Certara
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
- Ticker
- $CERT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,546
- Headquarters
- Radnor, United States
- Website
- www.certara.com
Certara Metrics
BasicAdvanced
$1.2B
-
-$0.43
1.41
-
Price and volume
Market cap
$1.2B
Beta
1.41
52-week high
$13.88
52-week low
$4.45
Average daily volume
2.8M
Financial strength
Current ratio
2.551
Quick ratio
2.441
Long term debt to equity
0.306
Total debt to equity
0.312
Interest coverage (TTM)
0.60%
Profitability
EBITDA (TTM)
88.349
Gross margin (TTM)
61.61%
Net profit margin (TTM)
-16.22%
Operating margin (TTM)
4.27%
Effective tax rate (TTM)
-57.80%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
0.77%
Return on equity (TTM)
-2.21%
Valuation
Price to revenue (TTM)
2.996
Price to book
1.26
Price to tangible book (TTM)
-12.6
Price to free cash flow (TTM)
23.155
Free cash flow yield (TTM)
4.32%
Free cash flow per share (TTM)
0.345
Growth
Revenue change (TTM)
11.09%
Earnings per share change (TTM)
-997.74%
3-year revenue growth (CAGR)
6.20%
3-year earnings per share growth (CAGR)
53.42%
What the Analysts think about Certara
Analyst ratings (Buy, Hold, Sell) for Certara stock.
Analyst projections of the future price of Certara stock.
Bulls say / Bears say
Software bookings grew 9% year-over-year to $50.7 million in Q2 2026, demonstrating strong demand for Certara’s biosimulation software (Certara IR)
Completed a $100 million share repurchase program and authorized an additional $50 million under its board-approved buyback, underscoring management’s confidence in the equity’s valuation (SEC filing)
Reappointed to a four-year framework service contract with the European Medicines Agency and ECDC, expanding Certara’s real-world evidence offerings and strengthening its regulatory services pipeline (Certara announcement)
GAAP net loss of $6.1 million in Q2 2026 from continuing operations highlights ongoing unprofitability for shareholders (SEC filing)
Adjusted diluted EPS of $0.08 in Q2 2026 missed the $0.09 consensus by $0.01, reflecting weaker-than-expected profitability (MarketBeat)
Services revenue declined 3% year-over-year to $44.5 million in Q2 2026, indicating weakness in Certara’s services segment (SEC filing)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.
Certara Financial Performance
Revenues and expenses
Certara Earnings Performance
Company profitability
Upcoming events
No upcoming events
Certara News
AllArticlesVideos
Funds containing Certara
AllUSDEURGBP
Fund name | Fund size | $CERT weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.11% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.11% |
iShares Healthcare Innovation£DRDR | £1B | 0.11% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.05% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.